NCT02608385View on ClinicalTrials.gov

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

April 1, 2022

Study Completion Date

November 30, 2026

Conditions
Solid Tumor
Interventions
RADIATION

Stereotactic body radiotherapy (SBRT)

Patients will receive 3 or 5 doses of SBRT to the chosen metastases.

DRUG

Pembrolizumab

Pembrolizumab (200 mg) given every 3 weeks.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER